<b>Objective</b>: Based on previous findings on the Lingguizhugan (LGZG)-mediated gut-liver axis, this study clarifies the therapeutic mechanisms of LGZG in metabolic dysfunction-associated steatotic liver disease (MASLD), with a focus on the gut microbiota-bile acid-TGR5 (GPBAR1) axis. Here, GPBAR1 is linked to metabolic dysfunction-associated steatotic liver disease.